Preparation and characterization of bosentan monohydrate/ε‐polycaprolactone nanoparticles obtained by electrospraying

Giménez, Virna Margarita Martín; Sperandeo, Norma R.; Faudone, Sonia Nerina; Noriega, Sandra; Manucha, Walter; Kassuha, Diego Enrique

doi:10.1002/btpr.2748

Cited by 10 publications

(4 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another very useful method for obtaining PCL NPs is the electrohydrodynamic technique of electrospraying [118][119][120][121]. In this regard, melatonin has also been encapsulated in PCL NPs by this method to improve the therapeutic efficacy of synthetic tissue grafts.…”

Section: Polycaprolactone/melatoninmentioning

confidence: 99%

Melatonin-Loaded Nanocarriers: New Horizons for Therapeutic Applications

et al. 2021

Self Cite

View full text Add to dashboard Cite

The use of nanosized particles has emerged to facilitate selective applications in medicine. Drug-delivery systems represent novel opportunities to provide stricter, focused, and fine-tuned therapy, enhancing the therapeutic efficacy of chemical agents at the molecular level while reducing their toxic effects. Melatonin (N-acetyl-5-methoxytriptamine) is a small indoleamine secreted essentially by the pineal gland during darkness, but also produced by most cells in a non-circadian manner from which it is not released into the blood. Although the therapeutic promise of melatonin is indisputable, aspects regarding optimal dosage, biotransformation and metabolism, route and time of administration, and targeted therapy remain to be examined for proper treatment results. Recently, prolonged release of melatonin has shown greater efficacy and safety when combined with a nanostructured formulation. This review summarizes the role of melatonin incorporated into different nanocarriers (e.g., lipid-based vesicles, polymeric vesicles, non-ionic surfactant-based vesicles, charge carriers in graphene, electro spun nanofibers, silica-based carriers, metallic and non-metallic nanocomposites) as drug delivery system platforms or multilevel determinations in various in vivo and in vitro experimental conditions. Melatonin incorporated into nanosized materials exhibits superior effectiveness in multiple diseases and pathological processes than does free melatonin; thus, such information has functional significance for clinical intervention.

show abstract

Section: Polycaprolactone/melatoninmentioning

confidence: 99%

Melatonin-Loaded Nanocarriers: New Horizons for Therapeutic Applications

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Prostacyclin (PGI 2 ) analogue [27,28,29,30], PDE5 inhibitors [31,32], ERA [33], oligonucleotides [34,35], pitavastatin [36,37], imatinib [38], rapamycin [39], and fasudil [40]-loaded NPs have been reported to be effective in animal PAH models and in vitro studies (Table 1). All of the data in the studies were obtained in animal models of PAH or in vitro studies and have not yet been translated to human trials.…”

Section: Nano-dds For Pah Treatmentmentioning

confidence: 99%

“…Bosetntan-loaded NPs: Bosentan monohydrate-loaded ε-polycaprolactone (PLC) NPs are made by electrospraying technique [33].…”

Section: Nano-dds For Pah Treatmentmentioning

confidence: 99%

Current Treatment Strategies and Nanoparticle-Mediated Drug Delivery Systems for Pulmonary Arterial Hypertension

Nakamura

Akagi

Ejiri

et al. 2019

IJMS

View full text Add to dashboard Cite

There are three critical pathways for the pathogenesis and progression of pulmonary arterial hypertension (PAH): the prostacyclin (prostaglandin I2) (PGI2), nitric oxide (NO), and endothelin pathways. The current approved drugs targeting these three pathways, including prostacyclin (PGI2), phosphodiesterase type-5 (PDE5) inhibitors, and endothelin receptor antagonists (ERAs), have been shown to be effective, however, PAH remains a severe clinical condition and the long-term survival of patients with PAH is still suboptimal. The full therapeutic abilities of available drugs are reduced by medication, patient non-compliance, and side effects. Nanoparticles are expected to address these problems by providing a novel drug delivery approach for the treatment of PAH. Drug-loaded nanoparticles for local delivery can optimize the efficacy and minimize the adverse effects of drugs. Prostacyclin (PGI2) analogue, PDE5 inhibitors, ERA, pitavastatin, imatinib, rapamycin, fasudil, and oligonucleotides-loaded nanoparticles have been reported to be effective in animal PAH models and in vitro studies. However, the efficacy and safety of nanoparticle mediated-drug delivery systems for PAH treatment in humans are unknown and further clinical studies are required to clarify these points.

show abstract

“…This is because the nanostructures act as protective coatings against different destabilizing factors, such as pH, enzymes, hydrolysis, etc. ; this also results in prolonged pharmacological effects [16]. In addition, therapeutic nanoformulations usually have less toxicity than conventional pharmaceutical formulations.…”

mentioning

confidence: 99%